glp-1 naion medicine and non-arteritic anterior ischemic optic neuropathy: Literature review and perspectives Danny D. | 👁️ Important

The battle over America's booming weight-loss drug market has a significant update, with a move thats likely to cause a shift across the healthcare and corporate benefits landscape: Cigna, one of Americas biggest insurers, is dropping coverage for GLP-1 obesity drugs, even for its own staff

Michael E

These findings underscore the potential for GLP-1 RAs to offer tailored protection against complex diabetic complications, marking an advancement in personalized medicine for managing diabetes-acute kidney disease.

Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.

What is a GLP-1 Receptor Agonist

Research to better understand and ultimately mitigate this heightened susceptibility is an important priority for new drug development in this area, and novel approaches to model the impact of endogenous hormone signaling will be critical to developing better treatments for more people